Targeted Inhibition of the DNA Damage Response Pathway: A Novel Intervention in the Treatment of Pediatric Leukemias |
National Cancer Institute / Andre Nussenzweig, Ph.D. |
Reach Grants |
2014 |
Maryland |
Targeting Chondroitin Sulphate Proteoglycan 4 (CSPG4) in Glioblastoma |
University of North Carolina / Gianpietro Dotti, MD & Barbara Savoldo, MD/PhD |
Reach Grants |
2017 |
North Carolina |
Adoptive Immunotherapy of Tr1 Cells to Improve Outcome of Allo-HSCT Treatment for Pediatric AML |
Stanford University / Maria-Grazia Roncarolo, MD & Rosa Bachetta, MD |
Reach Grants |
2015 |
California |
Identification of Rhabdomyosarcoma Therapies Using an Efficient Mouse and Drosophila Repurposing Screen |
Memorial Sloan-Kettering Cancer Center / Mary Baylies, Ph.D. |
Reach Grants |
2014 |
New York |
Identifying a Therapeutic Partner for TAK228 for Pediatric Phase II Brain Tumor Studies |
The Johns Hopkins University School of Medicine / Eric H. Raabe, MD/PhD |
Reach Grants |
2018 |
Maryland |
Targeting PI3Kdelta in Childhood Acute Lymphoblastic Leukemia |
Children’s Hospital Los Angeles / Yong-mi Kim, MD & Nora Heisterkamp, PhD |
Reach Grants |
2015 |
California |
Circumventing Pediatric Solid Tumor Microenvironment Resistance by Combinatorial CAR NK and Immunomodulating Therapy |
New York Medical College / Mitchell Cairo, MD |
Reach Grants |
2023 |
New York |
Targeting RNA Helicase DDX3 to Treat Recurrent High Grade Sarcoma
|
The Johns Hopkins University School of Medicine / David Loeb, MD, PhD |
Reach Grants |
2013 |
Maryland |
Feasibility Study of Dual Inhibition of MDM2 and Tubulin in Treatment of AML |
Emory University / Muxiang Zhou, MD |
Reach Grants |
2023 |
Georgia |
Preclinical Development of Targeted Therapy for Neuroblastoma with ALK and CDK4/6 Dual Pathway Inhibition
|
Children’s Hospital of Philadelphia / Yael Mossé, MD |
Reach Grants |
2013 |
Pennsylvania |